MAC Clinical Research the UK’s leading clinical trials organisation is proud to announce achieving Cyber Essentials security industry certification.

Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced statistically significant results on key efficacy endpoints in severe ED patients after a single administration of IPED2015. Moreover, no observations of critical adverse events were recorded.   ...

Dr John Connell (Chief Scientific Officer) and MAC's wider team of clinical development experts attended this years Clinical Trials Europe conference in Barcelona, Spain.

...

Make a bright future for yourself with a rewarding career at MAC Clinical Research

...

In recognition of 40 years devoted to early phase clinical research, Peter Dewland, BSc, MA, MBBS, FFPM, DCPSA, Senior Director of Early Phase Research at MAC Clinical Research, has been elected as Chair of the Phase I Advisory Group to the Health Research Authority (HRA).

The Phase I Advisory Group was established by the HRA as a forum to discuss issues relating to the ethical review of Phase I trials in the UK. The membership...

Teams of clinical trials experts and research scientists from MAC will be attending a broad range of meetings and conferences in 2019. Some of the main events from our calendar can be found on the MAC Meetings and Conferences web-page. We will include more events for 2019 in due course, so please check this page regularly for updates. If you are attending any of these events and would like to meet with us, please follow the li...

"Current challenges in running early phase studies in patients rather than healthy volunteers"

Photo gallery from CTAD 2018 in Barcelona on 25th October.

October 24, 2018 MANCHESTER, ENGLAND 

Across every clinical trial, Pharma and Biotech have a dire need to access patients in efficient numbers and to conduct their study to the highest quality possible. Every sponsor faces the same problems, these being the lack of high performing sites available, with eligible patients to power studies forward, leading to study delays, unforeseen and extra study costs and importantly drugs not...

...